Public annual accounts

ER-PHARMA financials

Name: ER-PHARMA financials
Creator: Upswitch
License: https://www.upswitch.app/terms-and-conditions

A multi-period view of the public annual-account figures reported for ER-PHARMA, with comparable measures and links to available source documents.

Company overview

Registry number

0791284824

Fiscal coverage

2024–2025

Public sources

cbso_bulk

Data updated

Jul 29, 2026

Financial evidence

Latest movements for ER-PHARMA

2025 versus 2024

Operating line: €24,592
EBITDA: €23,862
Total assets: €75,903
Equity: €55,819

EBITDA margin +97% · Equity ratio +73.5%

Multi-year filings

Filed annual accounts by fiscal year

Public regulator-filed figures across 2 years.

Source: NBB/CBSO

Fiscal year	Gross margin	EBITDA	Total assets	Equity	Filing
202531 Dec 2025	€24,592	€23,862	€75,903	€55,819	-
202431 Dec 2024	€24,655	€24,222	€74,540	€41,825	-

Gross margin line from gross margin (abbreviated schema). This is not reported turnover, so it is not used as a public valuation base.EBITDA basis: operating profit plus full add-backs.

Figures reproduce public filings and may use country-specific accounting definitions. They are not audited by Upswitch.

Public company datasets

Explore the underlying reports

Valuation

2 valuation checkpoints · 2024 to 2025 · Method family

Open report